IQ-AI Limited (LON:IQAI) said its Imaging Biometrics (IB) subsidiary, a provider of ready-to-use software to the healthcare industry, had its software featured in the top-award-winning article of a paper.
IB’s product is a vascular mapping software able to identify and distinguish recurrent high-grade brain tumour from benign treatment effects.
The article was published in the March 2020 issue of the American Journal of Neuroradiology, which assigned it the Lucien Levy Award, recognising it as the best original research paper accepted in 2019.
“Our relative cerebral blood volume maps have the potential to aid clinical decision-making before surgery, during recovery, and during follow-up treatment,” said Michael Schmainda, chief executive of IB.
“This optimised workflow certainly has the potential of becoming the consensus methodology, as the paper cites.”
Shares advanced 5% to 2.2p on Wednesday afternoon.